Physician profile
James E Fields
NPI 1770673600
$1,803.29
in general payments reported to CMS, 2019-2025
26 companies · $261 in 2025
The $261 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $251 · 2021: $345 · 2022: $154 · 2023: $393 · 2024: $207 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $225.40 | 2019-2023 | |
| Pfizer INC. | $217.67 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $175.00 | 2025 | Jornay Pm |
| Tris Pharma INC | $131.87 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $131.06 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $128.73 | 2021-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $121.73 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $112.78 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $74.03 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $54.63 | 2019-2021 | |
| Sanofi Pasteur INC. | $52.06 | 2023-2025 | |
| Ucb, INC. | $42.65 | 2020-2021 | |
| Seqirus USA INC | $41.21 | 2022-2025 | Flucelvax |
| Astrazeneca Pharmaceuticals Lp | $41.01 | 2023-2024 | Flumist Quadrivalent |
| Adlon Therapeutics L.P. | $39.63 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.28 | 2022-2023 | Bexsero |
| Genentech USA, INC. | $28.23 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $28.08 | 2021-2023 | |
| Mission Pharmacal Company | $18.75 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $18.58 | 2019 | |
| Cranial Technologies, INC | $16.12 | 2024 | Doc Band |
| Alk-Abello, INC | $16.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.85 | 2024 | |
| Ironwood Pharmaceuticals, INC | $15.02 | 2024 | |
| Biomarin Pharmaceutical INC. | $14.93 | 2024 | Voxzogo 1.2mg |
| Sage Therapeutics, LLC | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.